down arrow

Neoleukin Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US64049K1043
USD
21.16
1.92 (9.98%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

20.0622.51

52 Week

6.8837.20
Valuation
Technical
Day's Volume

CASH

95.01 k

Shareholding (Mar 2025)

FII

4.90%

Held by 37 FIIs

DII

67.9%

Held by 18 DIIs

Promoter

11.15%

How big is Neoleukin Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Neoleukin Therapeutics, Inc. has a market capitalization of 386.45 million and reported net sales of 0.93 million with a net profit of -80.87 million over the latest four quarters. The company has shareholder's funds of 310.38 million and total assets of 336.44 million as of Dec 24.

Market Cap: As of Jun 18, Neoleukin Therapeutics, Inc. has a market capitalization of 386.45 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Neoleukin Therapeutics reported net sales of 0.93 million and a net profit of -80.87 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 310.38 million and total assets of 336.44 million.

Read More

What does Neoleukin Therapeutics, Inc. do?

22-Jun-2025

Neoleukin Therapeutics, Inc. is a biopharmaceutical company that develops computationally-designed protein therapeutics for immuno-oncology, inflammation, and autoimmunity. It has a market cap of $386.45 million and reported a net profit loss of $23 million as of March 2025.

Overview:<BR>Neoleukin Therapeutics, Inc. is a biopharmaceutical company focused on developing computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 386.45 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: -27.71% <BR>Price to Book: 1.32 <BR><BR>Contact Details:<BR>Address: 1616 Eastlake Ave E Ste 360, SEATTLE WA: 98102-3795 <BR>Tel: 1 206 7322133 <BR>Website: https://www.neoleukin.com/

Read More

Who are in the management team of Neoleukin Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Neoleukin Therapeutics, Inc. includes Mr. Todd Simpson (Independent Chairman), Dr. Jonathan Drachman (CEO), and several directors: Mr. Martin Babler, Ms. Erin Lavelle, Ms. M. Cantey Boyd, Dr. Sarah Noonberg, and Dr. Lewis Williams. This team combines executive leadership with independent directors for effective governance.

As of March 2022, the management team of Neoleukin Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Todd Simpson, Independent Chairman of the Board<BR>- Dr. Jonathan Drachman, President, Chief Executive Officer, and Director<BR>- Mr. Martin Babler, Director<BR>- Ms. Erin Lavelle, Director<BR>- Ms. M. Cantey Boyd, Independent Director<BR>- Dr. Sarah Noonberg, Independent Director<BR>- Dr. Lewis Williams, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the company's governance and strategic direction.

Read More

Is Neoleukin Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

Neoleukin Therapeutics, Inc. is currently overvalued at $17.22 due to significant financial challenges, including a price-to-book ratio of 1.57, an EV to EBITDA of -1.95, and a return on equity of -27.71%, all while underperforming compared to its peers and the S&P 500.

As of 1 August 2019, Neoleukin Therapeutics, Inc. has moved from a risky valuation grade to one that does not qualify. The company is currently overvalued, given its significant financial challenges reflected in its ratios. The price-to-book value stands at 1.57, while the EV to EBITDA is a concerning -1.95, indicating that the company is not generating positive earnings before interest, taxes, depreciation, and amortization. Additionally, the return on equity (ROE) is at -27.71%, highlighting the company's struggles in generating profit from shareholders' equity.<BR><BR>In comparison to its peers, Neoleukin's valuation metrics are alarming. For instance, CorMedix, Inc. shows a P/E ratio of 55.03, while Poseida Therapeutics, Inc. has a P/E of -15.24, both indicating a stark contrast in performance and valuation. Furthermore, Neoleukin's recent stock performance has lagged significantly behind the S&P 500, with a year-to-date return of -24.67% compared to the index's 2.44%. Overall, the combination of poor financial ratios and underperformance relative to peers suggests that Neoleukin Therapeutics, Inc. is overvalued at its current price of $17.22.

Read More

Is Neoleukin Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 22, 2025, Neoleukin Therapeutics shows a mildly bullish technical trend despite conflicting indicators, while significantly underperforming the S&P 500 with a 1-year return of -54.77% compared to its 17.14%.

As of 22 August 2025, the technical trend for Neoleukin Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD remains bearish, while the monthly MACD shows a mildly bullish stance. Daily moving averages indicate a mildly bullish trend. However, the weekly Bollinger Bands and KST are bearish, and Dow Theory shows a mixed signal with a mildly bearish weekly and mildly bullish monthly outlook. Overall, the current technical stance is mildly bullish, but the strength is tempered by conflicting indicators.<BR><BR>In terms of performance, Neoleukin has underperformed significantly compared to the S&P 500 across all multi-period returns, with a 1Y return of -54.77% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 420 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-30.88%

stock-summary
Price to Book

1.54

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-22 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.49%
0%
6.49%
6 Months
2.92%
0%
2.92%
1 Year
-5.28%
0%
-5.28%
2 Years
51.14%
0%
51.14%
3 Years
127.48%
0%
127.48%
4 Years
-79.69%
0%
-79.69%
5 Years
76.33%
0%
76.33%

Neoleukin Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Neoleukin Therapeutics, Inc. technically bullish or bearish?

As of 22 August 2025, the technical trend for Neoleukin Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD remains bearish, while the monthly MACD shows a mildly bullish stance. Daily moving averages indicate a mildly bullish trend. However, the weekly Bollinger Bands and KST are bearish, and Dow Theory shows a mixed signal with a mildly bearish weekly and mildly bullish monthly outlook. Overall, the current technical stance is mildly bullish, but the strength is tempered by conflicting indicators. In terms of performance, Neoleukin has underperformed significantly compared to the S&P 500 across all multi-period returns, with a 1Y return of -54.77% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-186.08%
EBIT to Interest (avg)
-60.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.47%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.57
EV to EBIT
-1.88
EV to EBITDA
-1.95
EV to Capital Employed
73.99
EV to Sales
168.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3941.37%
ROE (Latest)
-27.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 24 Schemes (16.04%)

Foreign Institutions

Held by 37 Foreign Institutions (4.9%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -18.92% vs -780.95% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.30",
          "val2": "-19.30",
          "chgp": "-31.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.00",
          "val2": "-18.50",
          "chgp": "-18.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-21,766.50%",
          "chgp": "2,176.65%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -106.89% vs 34.24% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-79.40",
          "val2": "-52.30",
          "chgp": "-51.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-75.10",
          "val2": "-36.30",
          "chgp": "-106.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-89,302.70%",
          "val2": "0.00%",
          "chgp": "-8,930.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.90
-100.00%
Operating Profit (PBDIT) excl Other Income
-25.30
-19.30
-31.09%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-22.00
-18.50
-18.92%
Operating Profit Margin (Excl OI)
0.00%
-21,766.50%
2,176.65%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -18.92% vs -780.95% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.90
0.00
Operating Profit (PBDIT) excl Other Income
-79.40
-52.30
-51.82%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-75.10
-36.30
-106.89%
Operating Profit Margin (Excl OI)
-89,302.70%
0.00%
-8,930.27%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -106.89% vs 34.24% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Neoleukin Therapeutics, Inc. stock-summary
stock-summary
Neoleukin Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
Company Coordinates stock-summary
Company Details
1616 Eastlake Ave E Ste 360 , SEATTLE WA : 98102-3795
stock-summary
Tel: 1 206 7322133
stock-summary
https://www.neoleukin.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."